TY  - CHAP
M1  - Book, Section
TI  - Chapter 62. Glaucoma
A1  - McGee, Karen H.
A2  - Sutton, S. Scott
PY  - 2011
T2  - McGraw-Hill's NAPLEX® Review Guide
AB  - Glaucoma  is  a  progressive  eye  disease.  It  affects  three  million  Americans  and  is  the  second  leading  cause  of  blindness  in  the  United  States.  There  are  two  major  types  of  glaucoma:  primary  open  angle  glaucoma  (POAG)  and  angle  closure  glaucoma.  The  most  common  type,  POAG,  will  be  the  focus  of  this  discussion.  Angle  closure  glaucoma,  though  less  common,  is  considered  a  medical  emergency.  Angle  closure  glaucoma  may  result  in  sudden  loss  or  blurring  of  vision,  significantly  elevated  eye  pressures,  nausea  and  vomiting.  Both  types  of  glaucoma  may  result  in  optic  nerve  damage  and  permanent  blindness  if  not  treated.  Glaucoma  does  not  cause  symptoms  in  the  majority  of  patients.  It  is  important  for  pharmacists  to  counsel  patients  about  routine  eye  examinations  and  glaucoma  screenings  for  early  detection.  There  are  several  risk  factors  associated  with  the  development  of  glaucoma.  These  include  age  >40  years,  African  American  or  Asian  race,  diabetes,  hypertension,  elevated  intraocular  pressure,  myopia,  and  family  history  in  a  first-degree  relative.  Treatment  is  aimed  at  reduction  in  intraocular  pressure.  Eye  drops  and  surgery  are  the  most  common  treatments.  The  most  potent  eye  drops  are  the  prostaglandin  analogs.  The  pharmacist's  role  in  the  care  of  patients  with  glaucoma  includes  disease  and  medication  counseling,  review  of  eye  drop  administration  technique,  eye  drop  adherence  evaluations,  and  recommendations  for  routine  eye  examinations.1,2  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=7256102
ER  -